Episode
2377: hVIVO Lands Landmark Phase III Trial
- Podcast
- The Vox Markets Podcast
- Published
- Apr 22, 2026
- Duration seconds
- 439
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8893869
Actions
POST https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2377-hvivo-lands-landmark-phase-iii-trial/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2377-hvivo-lands-landmark-phase-iii-trial.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
hVIVO has been selected to run the world’s first pivotal Phase III human challenge trial in whooping cough, marking a major scientific milestone and its largest study to date. The contract strengthens revenue visibility into 2026–27 while underlining the growing importance of human challenge trials in accelerating vaccine approvals globally.